Rapamycin for the treatment of lymphangioleiomyomatosis
AssigneeAI Therapeutics, Inc.
InventorsThomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
Claims7
A method for treating Lymphangioleiomyomatosis in a human subject in need of such treatment, the method comprising administering to the subject by inhalation a pharmaceutical dry powder composition comprising microparticles of sirolimus, particles of a carrier, and one or more optional excipients, wherein the microparticles of sirolimus have a mean diameter of from 1 to 5 microns, and wherein the sirolimus is the only therapeutic agent in the composition.
Dependencies are inferred from the claim text.